User:Mr. Ibrahem/Aducanumab

Aducanumab, sold under the brand name Aduhelm, is a medication used to treat Alzheimer's disease (AD). Benefits are unclear as of 2024, with only decreased amyloid plaque shown in mild disease. It is given by injection into a vein.

Common side effects include brain swelling, headache, bleeding in the brain, and falls. Other side effects may include angioedema. It is a monoclonal antibody directed against amyloid beta (Aβ).

Aducanumab was approved for medical use in the United States in 2021. In 2021 Europe voted against approval and it is not available in Canada as of 2024. In the United States it costs about 56,000 USD per year as of 2021; though in December of that year they decreased the price to 28,200 USD. The Office of Inspector General, U.S. Department of Health and Human Services has been asked to investigate interaction between the manufacturer and the FDA prior to its approval.